Forest's Namenda gains US patent extension to 2015
This article was originally published in Scrip
Executive Summary
The US Patent and Trademark Office has reviewed the regulatory timeline governing approval of Forest Laboratories Alzheimer's drug Namenda (memantine HCl), and has determined that the patent (the '703) is entitled to the full five years of patent term extension, bringing the expiration date to April 11th, 2015.